Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 89 citing Danne: Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups.... (0.08 sec) 

Engineering predictability and protraction in a basal insulin analogue: the …


P Kurtzhals - International Journal of Obesity, 2004 - nature.com
The suboptimal nature of the absorption profiles of human insulin formulations following subcutaneous
administration has prompted the development of insulin analogues better suited for therapeutic
use in diabetes mellitus. A particular challenge has been to engineer long-acting agents ...
Cited by 65 - Related articles - BL Direct - All 5 versions

A critical appraisal of the role of insulin analogues in the management of diabetes …

- adisonline.com [PDF] 
R Oiknine, M Bernbaum, AD Mooradian - Drugs, 2005 - pt.wkhealth.com
Insulin is one of the oldest and best studied treatments for diabetes mellitus. Despite many improvements
in the management of diabetes, the nonphysiological time-action profiles of conventional insulins
remain a significant obstacle. However, the advent of recombinant DNA technology made ...
Cited by 60 - Related articles - All 5 versions

Insulin detemir: from concept to clinical experience


P Home, P Kurtzhals - Expert Opin. Pharmacother., 2006 - Informa Pharma Science
Insulin detemir (Levemir®, Novo Nordisk) is a novel, biologically engineered analogue of human
insulin that has been successfully developed for clinical use in diabetes as a basal insulin. Its
unique mechanism of prolongation of action, achieved through acylation to give ...
Cited by 58 - Related articles - BL Direct - All 5 versions

Insulin detemir compared with NPH insulin in children and adolescents with type 1 …


KJ Robertson, E Schoenle, Z Gucev, L … - Diabetic …, 2007 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Cited by 54 - Related articles - BL Direct - All 5 versions

[BOOK] Pediatric endocrinology


F Lifshitz - 2006 - books.google.com
Informa Healthcare USA, Inc. 52 Vanderbilt Avenue New York, NY 10017 © 2007 by Informa
Healthcare USA, Inc. Informa Healthcare is an Informa business No claim to original US Government
works Printed in the United States of America on acid-free paper 10 98765432 ...
Cited by 41 - Related articles - All 2 versions

Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data …


A Dornhorst, HJ Luddeke, S Sreenan, C … - … journal of clinical …, 2007 - interscience.wiley.com
PREDICTIVE TM (Predictable Results and Experience in Diabetes through Intensification and
Control to Target: An International Variability Evaluation) is a large, multi-national,
open-label, prospective, observational study assessing the safety and efficacy of insulin ...
Cited by 34 - Related articles - BL Direct - All 5 versions

Insulin detemir--a new basal insulin analog


JD Goldman-Levine, KW Lee - The Annals of pharmacotherapy, 2005 - Harvey Whitney Books
Published Online, 18 January 2005, www.theannals.com, DOI 10.1345/aph.1E334. The Annals
of Pharmacotherapy: Vol. 39, No. 3, pp. 502-507. DOI 10.1345/aph.1E334 © 2005 Harvey Whitney
Books Company. ... OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical ...
Cited by 26 - Related articles - All 6 versions

Insulin therapy: current alternatives


FJ Gómez-Pérez, JA Rull - Archives of medical research, 2005 - Elsevier
In normal humans, blood glucose and insulin are maintained within a narrow range despite wide
variations in physical activity and dietary intake. At present, reproducing this pattern is an impossible
task in type 1 diabetes and extremely difficult in type 2 DM. New approaches using novel ...
Cited by 25 - Related articles - All 12 versions

Insulin detemir: a new basal insulin analogue


H Soran, N Younis - Diabetes Obesity and Metabolism, 2006 - interscience.wiley.com
Basal insulin therapy is an integral part of the intensive management of type 1 diabetes and it
is also often used in type 2 diabetes. An ideal insulin regimen in patients with diabetes would
mirror the 24-h insulin profile of a non-diabetic person, thereby preventing ...
Cited by 19 - Related articles - BL Direct - All 4 versions

Intensive insulin therapy today:'basal-bolus' using multiple daily injections or CSII?


E Renard - Diabetes and Metabolism, 2005 - Elsevier
Intensive insulin therapy aiming at normoglycemia in order to prevent long-term complications
is not questionable for the management of type 1 diabetes mellitus nowadays. The gold standard
mode of insulin therapy in this view is CSII using fast-acting analogues. Whether this ...
Cited by 17 - Related articles - BL Direct - All 3 versions


Result Page: 

1

2

3

4

5

6

7

8

9

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google